vTv Therapeutics Inc.

NASDAQ:VTVT

Biotechnology

Healthcare
$16.23 +1.47%

+$0.50 today

Market cap
$64.17M
Beta
0.27
P/E (TTM)
128.7
EPS (TTM)
$0.27
52W Low $14.00High $44.00

Volume 0.02M

Average 0.05M

VTVT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

vTv Therapeutics Inc.NASDAQ: VTVT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 8.42M shares rose 28.0% year over year, behind the +30.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +63.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +28.0% toward the trailing-twelve-month pace of +30.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
8.42M+0.0% QoQ
Last fiscal yearDec 2025
8.42M+46.0% YoY
LTMMar 2026
7.87M+30.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.0%——
1 year+46.0%——
3-year CAGR+63.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
8.42M USD
Year-over-year change
+46.0%
4-year CAGR
+52.3%

Weighted Avg Shares vs competitors

How VTVT compares with its peers on the latest reported figures

  • VTVT's LTM Mar 2026 weighted avg shares of 7.87M shares is the 7th highest of the 9 companies compared; the peer median is 29.82M shares.
  • Its year-over-year change of +30.1% is the 6th highest of 9, against a peer median of +36.2%.
  • Over three fiscal years its annual growth of +63.7% compares with a peer median of +12.5%.
VTVT Competitors Peer median
Weighted Avg Shares for VTVT and competitors
Company Period LTM YoY 3-year CAGR
OTLKOutlook Therapeutics, Inc.LTM Mar 202653.45M +120.6%+48.6%
HOWLWerewolf Therapeutics, Inc.LTM Jun 202647.17M +6.0%+16.8%
GANXGain Therapeutics, Inc.LTM Mar 202635.13M +38.4%+40.5%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
FBIOFortress Biotech, Inc.LTM Mar 202628.39M +34.1%+67.6%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
VTVTvTv Therapeutics Inc.LTM Mar 20267.87M +30.1%+63.7%
INKTMiNK Therapeutics, Inc.LTM Mar 20264.37M +15.1%+8.2%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding VTVT) 29.82M+36.2%+12.5%

Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.01M2.02M01.02M0
Cost of Revenue00000
Gross Profit4.01M2.02M01.02M0
Gross Margin100.0%100.0%—100.0%—
Research & Development13.32M12.36M13.6M11.55M17.86M
Selling, General & Admin12.34M12.2M11.91M13.65M14.95M
Operating Expenses25.67M24.56M25.5M25.2M32.81M
Depreciation & Amortization89K92K90K89K16K
EBITDA(17.52M)(24.77M)(25.86M)(22.52M)(31.06M)
EBITDA Margin-437.3%-1227.3%—-2214.0%—
Operating Income(21.66M)(22.54M)(25.5M)(24.18M)(32.81M)
Operating Margin-540.9%-1116.9%—-2377.6%—
Interest Income1K352K472K1.57M1.87M
Interest Expense12K15K13K06K
Other Income / Expenses4.05M(2.33M)(464K)1.58M1.73M
Income Before Tax(17.62M)(24.87M)(25.97M)(22.61M)(31.08M)
Pre-Tax Margin-439.9%-1232.6%—-2222.7%—
Income Tax Expense115K200K0100K0
Net Income(12.99M)(19.16M)(20.25M)(18.46M)(26.97M)
Net Margin-324.3%-949.7%—-1815.3%—
EPS (Basic)(8.29)(9.98)(9.71)(3.20)(3.20)
EPS (Diluted)(8.29)(9.98)(9.71)(3.20)(3.20)
Weighted Avg Shares1.57M1.92M2.08M5.77M8.42M
Weighted Avg Shares (Diluted)1.57M1.92M2.08M5.77M8.42M

vTv Therapeutics Inc.

NASDAQ:VTVT

Intrinsic Alpha fair value

Locked

Current Price

$16.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.